Track market-moving stories before they get noisy

NOT FOR DISSEMINATION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES OF AMERICA

TORONTO--(BUSINESS WIRE)--CI Global Asset Management (“CI GAM”) announces the following regular cash distributions for the month or quarter ending June 30, 2026 for the ETFs managed by CI GAM with a payment date of July 8, 2026. The payment will be made to unitholders of record on June 29, 2026. The ex-dividend date for all ETFs is June 29, 2026.

The following ETFs trade on the Toronto Stock Exchange with the exception of Invesco Long Term Government Bond Index ETF (PGL) and Invesco S&P Europe 350 Equal Weight Index ETF (EQE, EQE.F), which trade on the Cboe Canada exchange.

ETF

Trading
Symbol (1)

Distribution
Amount (per
unit in $)

Payment
Frequency

Fixed income

Invesco Canadian Government Floating Rate Index ETF – CAD

PFL

0.0390

Monthly

Invesco 1-5 Year Laddered Investment Grade Corporate Bond Index ETF – CAD

PSB

0.0480

Monthly

Invesco Long Term Government Bond Index ETF – CAD

PGL

0.0527

Monthly

Invesco US Treasury Floating Rate Note Index ETF (USD) – USD

IUFR.U

0.0619

Monthly

Invesco Canadian Core Plus Bond ETF – CAD

ICCB

0.0686

Monthly

Invesco Global Bond ETF – CAD

ICGB

0.0656

Monthly

ESG fixed income

Invesco ESG Canadian Core Plus Bond ETF – CAD

BESG

0.0548

Monthly

Invesco ESG Global Bond ETF – CAD

IWBE

0.0531

Monthly

Equity income

Invesco Canadian Dividend Index ETF – CAD

PDC

0.1339

Monthly

Invesco S&P/TSX Canadian Dividend Aristocrats ESG Index ETF – CAD

ICAE

0.0677

Monthly

Invesco S&P US Dividend Aristocrats ESG Index ETF – CAD

IUAE

0.0344

Monthly

Invesco S&P US Dividend Aristocrats ESG Index ETF – CAD Hedged

IUAE.F

0.0315

Monthly

Invesco S&P International Developed Dividend Aristocrats ESG Index ETF – CAD

IIAE

0.0746

Monthly

Invesco S&P International Developed Dividend Aristocrats ESG Index ETF –CAD Hedged

IIAE.F

0.0706

Monthly

Low-volatility equity

Invesco S&P 500 Low Volatility Index ETF – CAD

ULV.C

0.0616

Monthly

Invesco S&P 500 Low Volatility Index ETF – CAD Hedged

ULV.F

0.0844

Monthly

Invesco S&P 500 Low Volatility Index ETF – USD

ULV.U

0.0440

Monthly

Invesco S&P/TSX Composite Low Volatility Index ETF – CAD

TLV

0.1186

Monthly

ESG equity income

Invesco ESG NASDAQ 100 Index ETF – CAD

QQCE

0.0271

Quarterly

Invesco ESG NASDAQ 100 Index ETF – CAD Hedged

QQCE.F

0.0208

Quarterly

Invesco S&P 500 ESG Index ETF – CAD

ESG

0.1083

Quarterly

Invesco S&P 500 ESG Index ETF – CAD Hedged

ESG.F

0.0958

Quarterly

Invesco S&P/TSX Composite ESG Index ETF – CAD

ESGC

0.2058

Quarterly

Invesco S&P International Developed ESG Index ETF – CAD

IICE

0.1356

Quarterly

Invesco S&P International Developed ESG Index ETF – CAD Hedged

IICE.F

0.1453

Quarterly

Equal weight equity

Invesco S&P 500 Equal Weight Income Advantage ETF – CAD

EQLI

0.1637

Monthly

Invesco S&P 500 Equal Weight Income Advantage ETF – CAD Hedged

EQLI.F

0.1513

Monthly

Invesco S&P 500 Equal Weight Income Advantage ETF – USD

EQLI.U

0.1525

Monthly

Invesco S&P 500 Equal Weight Index ETF – CAD

EQL

0.1445

Quarterly

Invesco S&P 500 Equal Weight Index ETF – CAD Hedged

EQL.F

0.1168

Quarterly

Invesco S&P 500 Equal Weight Index ETF – USD

EQL.U

0.1036

Quarterly

Invesco S&P Europe 350 Equal Weight Index ETF – CAD

EQE

0.1725

Quarterly

Invesco S&P Europe 350 Equal Weight Index ETF – CAD Hedged

EQE.F

0.1696

Quarterly

Invesco S&P/TSX 60 Equal Weight Index ETF – CAD

EQLT

0.1459

Quarterly

Fundamental Index® methodology equity

Invesco RAFI Canadian Index ETF – CAD

PXC

0.3563

Quarterly

Invesco RAFI Global Small-Mid ETF – CAD

PZW

0.1394

Quarterly

Invesco RAFI Global Small-Mid ETF – CAD Hedged

PZW.F

0.0972

Quarterly

Invesco RAFI Global Small-Mid ETF – USD

PZW.U

0.0992

Quarterly

Invesco RAFI U.S. Index ETF II – CAD

PXS

0.1788

Quarterly

Invesco RAFI U.S. Index ETF II – USD

PXS.U

0.1276

Quarterly

Invesco RAFI U.S. Index ETF – CAD Hedged

PXU.F

0.2231

Quarterly

U.S. equity

Invesco NASDAQ 100 Income Advantage ETF – CAD

QQCI

0.2112

Monthly

Invesco NASDAQ 100 Income Advantage ETF – CAD Hedged

QQCI.F

0.1731

Monthly

Invesco NASDAQ 100 Income Advantage ETF – USD

QQCI.U

0.1740

Monthly

Invesco NASDAQ 100 Index ETF – CAD

QQC

0.0398

Quarterly

Invesco NASDAQ 100 Index ETF – CAD Hedged

QQC.F

0.1844

Quarterly

Invesco NASDAQ 100 Equal Weight Index ETF – CAD

QQEQ

0.0473

Quarterly

Invesco NASDAQ 100 Equal Weight Index ETF – CAD Hedged

QQEQ.F

0.0382

Quarterly

Invesco NASDAQ Next Gen 100 Index ETF – CAD

QQJR

0.0223

Quarterly

Invesco NASDAQ Next Gen 100 Index ETF – CAD Hedged

QQJR.F

0.0177

Quarterly

Invesco Russell 1000 Multifactor Index ETF – CAD

IUMF

0.0530

Quarterly

Invesco Russell 1000 Multifactor Index ETF – CAD Hedged

IUMF.F

0.0477

Quarterly

Global equity

Invesco Morningstar Global Energy Transition Index ETF – CAD

IGET

0.0375

Quarterly

Invesco Morningstar Global Energy Transition Index ETF – CAD Hedged

IGET.F

0.0350

Quarterly

Invesco Morningstar Global Next Gen AI Index ETF – CAD

INAI

0.0004

Quarterly

Invesco Morningstar Global Next Gen AI Index ETF – CAD Hedged

INAI.F

0.0013

Quarterly

International equity

Invesco International Developed Multifactor Index ETF – CAD

IIMF

0.1483

Quarterly

Invesco International Developed Multifactor Index ETF – CAD Hedged

IIMF.F

0.1462

Quarterly

  1 A ticker symbol ending with “.U” represents U.S.-dollar-denominated units. USD units of these ETFs are offered as a convenience for investors who wish to purchase with U.S. dollars and receive distributions and the proceeds of sale or redemption in U.S. dollars. The USD units are not hedged against changes in the exchange rate between the Canadian dollar and the U.S. dollar.

About CI Global Asset Management

CI Global Asset Management (“CI GAM”) is one of Canada’s leading investment management firms, providing a comprehensive suite of solutions – including mutual funds, exchange-traded funds and alternative investments – to help Canadians achieve their financial goals. Founded in 1965, CI GAM has built an enduring legacy of innovation, disciplined portfolio management and commitment to investor success. We partner with financial advisors, wealth management firms and institutions to serve more than 1.3 million investors. CI GAM is a subsidiary of Toronto-based CI Financial Corp., a diversified global asset and wealth management company. For more information, visit www.ci.com or follow us on LinkedIn.

Commissions, management fees and expenses all may be associated with an investment in exchange-traded funds (ETFs). You will usually pay brokerage fees to your dealer if you purchase or sell units of an ETF on recognized Canadian exchanges. If the units are purchased or sold on these Canadian exchanges, investors may pay more than the current net asset value when buying units of the ETF and may receive less than the current net asset value when selling them. Please read the prospectus before investing. Important information about an exchange-traded fund is contained in its prospectus. ETFs are not guaranteed; their values change frequently, and past performance may not be repeated.

This communication is intended for informational purposes only and does not constitute an offer to sell or the solicitation of an offer to purchase mutual funds managed by CI Global Asset Management and is not, and should not be construed as, investment, tax, legal or accounting advice, and should not be relied upon in that regard. Every effort has been made to ensure that the material contained in this document is accurate at the time of publication. Individuals should seek the advice of professionals, as appropriate, regarding any particular investment. Investors should consult their professional advisors prior to implementing any changes to their investment strategies. These investments may not be suitable to the circumstances of an investor.

Certain names, words, titles, phrases, logos, icons, graphics, or designs in this document may constitute trade names, registered or unregistered trademarks or service marks of CI Investments Inc., its subsidiaries, or affiliates, used with permission. All other marks are the property of their respective owners and are used with permission.

The indices referenced are products of S&P Dow Jones Indices LLC or its affiliates (“SPDJI”) and/or TSX, Inc., and have been licensed for use by CI Global Asset Management (“CI GAM”). S&P® and S&P 500® are trademarks of S&P Global, Inc. or its affiliates (“S&P”); Dow Jones® is a registered trademark of Dow Jones Trademark Holdings LLC (“Dow Jones”); TSX is a trademark of TSX, Inc., and these trademarks have been licensed for use by SPDJI and sublicensed for certain purposes by CI GAM. The CI ETFs are not sponsored or sold by SPDJI, Dow Jones, S&P, their respective affiliates or TSX, Inc., and none of such parties make any representation regarding the advisability of investing in such products nor do they have any liability for any errors, omissions, or interruptions of the indices.

Morningstar® is a registered trademark of Morningstar, Inc. The securities of each ETF are not in any way sponsored, endorsed, sold or promoted by Morningstar or any of its affiliates (collectively, "Morningstar"), and Morningstar makes no representation or warranty, express or implied, regarding the advisability of investing in securities generally or in the ETFs.

Russell® is a trademark of Frank Russell Company, part of London Stock Exchange Group. The Russell 1000 Dynamic‑Multifactor Index is calculated by Russell. Russell does not sponsor, endorse, or promote this product and is not affiliated with it and accepts no liability in relation to its use, operation, or trading. The applicable RAFI index is a service mark of RAFI Indices, LLC or its affiliates and is licensed for use by CI Global Asset Management. The Product is not sponsored, endorsed, sold or promoted by RAFI or its agents. RAFI makes no representation regarding the advisability of investing in the ETF. In no event will RAFI and its agents be liable for any damages, including direct, indirect, special, punitive and consequential damages (including lost profits) with respect to the Product or Index.

Nasdaq®, Nasdaq-100®, and related marks are registered trademarks of Nasdaq, Inc. (which, together with its affiliates, are referred to as the “Corporations”) and are licensed for use by CI Global Asset Management. The Product(s) have not been passed on by the Corporations as to their legality or suitability and are not issued, endorsed, sold, or promoted by the Corporations. THE CORPORATIONS MAKE NO WARRANTIES AND BEAR NO LIABILITY WITH RESPECT TO THE PRODUCT(S).

Invesco® and all associated trademarks are trademarks of Invesco Holding Company Limited, and used by CI Global Asset Management under licence.

The CI Exchange-Traded Funds are managed by CI Global Asset Management, a wholly owned subsidiary of CI Financial Corp.

CI Global Asset Management is a registered business name of CI Investments Inc.

©CI Investments Inc. 2026. All rights reserved.

Applied Materials, Inc. (AMAT) shares jump over 7,700% since 1997’s first institutional outlier signal.

PREMIUM

Read what the experts are trading this weekExclusive analysis from FXEmpire top analysts — curated insights you won't find on the free site.

In-depth analysis

Curated reports

Top analysts

Unlock Premium

AMAT provides materials engineering and solutions for advanced displays along with semiconductor manufacturing capabilities, which are drawing heavy AI-related demand. AMAT’s second-quarter fiscal 2026 earnings report showed quarterly revenue of $7.91 billion (an 11% year-over-year gain), non-GAAP per-share earnings of $2.86 (a 20% rise), along with quarterly revenue and EPS guidance of $8.95 billion and $3.36, respectively.

No wonder AMAT shares are up 121% so far this year – and they could rise more. MoneyFlows data shows how Big Money investors are again betting heavily on the stock.

Applied Materials Attracts Big Money Institutional volumes reveal plenty. In the last year, AMAT has enjoyed strong investor demand, which we believe to be institutional support.

Each green bar signals unusually large volumes in AMAT shares. They reflect our proprietary inflow signal, pushing the stock higher:

Source: www.moneyflows.com Plenty of technology names are under accumulation right now. But there’s a powerful fundamental story happening with Applied Materials.

Applied Materials Fundamental Analysis Institutional support and a healthy fundamental backdrop make this company worth investigating. As you can see, AMAT has had strong earnings growth and profits:

3-year EPS growth rate (+5.2%) Profit margin (+24.7%) Source: FactSet

Also, EPS is estimated to ramp higher this year by +34.3%.

Now it makes sense why the stock has been generating Big Money interest. AMAT has a track record of strong financial performance.

Marrying great fundamentals with MoneyFlows software has found some big winning stocks over the long term.

Applied Materials has been a top-rated stock at MoneyFlows for years. That means the stock has unusual buy pressure and growing fundamentals. We have a ranking process that showcases stocks like this on a weekly basis.

It’s up 7,740% since its first appearance on the rare Outlier 20 report in July 1997 and continues to draw inflows. Look at the trend over the last five years…this is an institutional cornerstone:

Source: www.moneyflows.com Tracking unusual volumes reveals the power of money flows.

This is a trait that most outlier stocks exhibit…the best of the best. Big Money demand drives stocks upward.

Applied Materials Price Prediction The AMAT action isn’t new at all. Big Money buying in the shares is signaling to take notice. Given the historical gains in share price and strong fundamentals, this stock could be worth a spot in a diversified portfolio.

Disclosure: the author holds no position in AMAT at the time of publication.

If you are a Registered Investment Advisor (RIA) or are a serious investor, take your investing to the next level and follow our free weekly MoneyFlows insights.

Related Articles

Nasdaq Index: Chip Stock Rout Sparks Bearish Analysis as Tech Stocks DivergeNasdaq 100, Dow Jones 30 and S&P 500 Forecasts – US Indices Drop After Iranian CommentsMSFT, AMZN and AAPL Forecasts – Majors in the US Mixed in PremarketAbout the Author

Lucas is a well-versed equity investor and educator. He currently is co-founder of research and analytics firm, MAPsignals.com, which focuses on finding outlier stocks by following the Big Money.

Editors’ Picks

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?

Before we discuss the reliability of brokerage recommendations and how to use them to your advantage, let's see what these Wall Street heavyweights think about Applied Materials (AMAT - Free Report) .

Applied Materials currently has an average brokerage recommendation (ABR) of 1.50, on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell, etc.) made by 38 brokerage firms. An ABR of 1.50 approximates between Strong Buy and Buy.

Of the 38 recommendations that derive the current ABR, 27 are Strong Buy and three are Buy. Strong Buy and Buy respectively account for 71.1% and 7.9% of all recommendations.

Brokerage Recommendation Trends for AMAT

Check price target & stock forecast for Applied Materials here>>>

While the ABR calls for buying Applied Materials, it may not be wise to make an investment decision solely based on this information. Several studies have shown limited to no success of brokerage recommendations in guiding investors to pick stocks with the best price increase potential.

Are you wondering why? The vested interest of brokerage firms in a stock they cover often results in a strong positive bias of their analysts in rating it. Our research shows that for every "Strong Sell" recommendation, brokerage firms assign five "Strong Buy" recommendations.

In other words, their interests aren't always aligned with retail investors, rarely indicating where the price of a stock could actually be heading. Therefore, the best use of this information could be validating your own research or an indicator that has proven to be highly successful in predicting a stock's price movement.

With an impressive externally audited track record, our proprietary stock rating tool, the Zacks Rank, which classifies stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), is a reliable indicator of a stock's near-term price performance. So, validating the Zacks Rank with ABR could go a long way in making a profitable investment decision.

ABR Should Not Be Confused With Zacks RankAlthough both Zacks Rank and ABR are displayed in a range of 1--5, they are different measures altogether.

Broker recommendations are the sole basis for calculating the ABR, which is typically displayed in decimals (such as 1.28). The Zacks Rank, on the other hand, is a quantitative model designed to harness the power of earnings estimate revisions. It is displayed in whole numbers -- 1 to 5.

It has been and continues to be the case that analysts employed by brokerage firms are overly optimistic with their recommendations. Because of their employers' vested interests, these analysts issue more favorable ratings than their research would support, misguiding investors far more often than helping them.

On the other hand, earnings estimate revisions are at the core of the Zacks Rank. And empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.

Furthermore, the different grades of the Zacks Rank are applied proportionately across all stocks for which brokerage analysts provide earnings estimates for the current year. In other words, at all times, this tool maintains a balance among the five ranks it assigns.

Another key difference between the ABR and Zacks Rank is freshness. The ABR is not necessarily up-to-date when you look at it. But, since brokerage analysts keep revising their earnings estimates to account for a company's changing business trends, and their actions get reflected in the Zacks Rank quickly enough, it is always timely in indicating future price movements.

Should You Invest in AMAT?In terms of earnings estimate revisions for Applied Materials, the Zacks Consensus Estimate for the current year has increased 2.2% over the past month to $12.1.

Analysts' growing optimism over the company's earnings prospects, as indicated by strong agreement among them in revising EPS estimates higher, could be a legitimate reason for the stock to soar in the near term.

The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #2 (Buy) for Applied Materials. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>

Therefore, the Buy-equivalent ABR for Applied Materials may serve as a useful guide for investors.

Three chip equipment maker stocks—Lam Research, Applied Materials, and KLA Corp.—were all surging on Wednesday after Citi hiked their price targets.

Several leading semiconductor equipment firms saw their shares hit record highs on Wednesday after a bullish report on the sector from investment firm Citi. ASML (ASML) stock was among those in rarefied air.

Citi analyst Atif Malik increased his bull-case estimates for wafer fabrication equipment (WFE) sales for 2026 and the next two years. He also raised his price targets on buy-rated Applied Materials (AMAT), KLA (KLAC) and Lam Research (LRCX).

↑ X NOW PLAYING The Best Investments Beyond AI

Malik upped his price target on Applied Materials to 710 from 550. On the stock market today, Applied Materials surged 4.4% to close at 592.92. Earlier in the session, AMAT stock notched an all-time high of 623.35.

He raised his price target on KLA to 290 from 206.40. KLA stock rose 0.6% to 238.73 on Wednesday. It is trading below its record high of 267.17, reached on Monday.

Malik increased his price target on Lam stock to 450 from 315. On Wednesday, Lam stock climbed 1.3% to 374.18. In intraday trading, it reached an all-time high of 397.54.

ASML Stock Spikes To Record High Elsewhere among chip gear stocks, ASML jumped 3.5% to close at 1,867.83. Earlier in the day, it hit a record high of 1,938.49.

Semiconductor equipment stocks are benefiting from chipmakers buying new gear to increase capacity to produce logic, memory and other chips for the artificial intelligence boom.

Malik predicted bull-case WFE sales of $145 billion this year, $200 billion in 2027 and $250 billion in 2028.

"We are more constructive on 2028 WFE given continued capacity constraints and expansion at both TSMC and memory makers, as well as recent progress at Intel and Samsung foundries," he said in a client note.

Other chip gear stocks hitting record highs on Wednesday included ACM Research (ACMR), MKS (MKSI), Teradyne (TER) and Tokyo Electron (TOELY).

Follow Patrick Seitz on X at @IBD_PSeitz for more stories on consumer technology, software and semiconductor stocks.

YOU MAY ALSO LIKE:

AMD Stock Upgraded To Buy On GPU Upside

Taiwan Semiconductor Sales Rise 30% In May, Remain On Target

Discover Profitable Trades Each Day With MarketDiem. See How.

Find Winning Stocks With MarketSurge Pattern Recognition & Custom Screens

Join IBD Live For Stock Ideas Each Morning Before The Open

Copyright ©2026 Investor's Business Daily, LLC. All rights reserved. 87990cbe856818d5eddac44c7b1cdeb8

Applied Materials is upgraded to Buy for long-term investors as price now aligns with fundamental performance. AMAT's record Q2 results, robust AI-driven WFE demand, and recurring service revenues reinforce its industry leadership and growth outlook. Despite trading at a discount to peers on EV/revenue, AMAT's forward growth acceleration presents a mispricing opportunity.

This week's news that Applied Materials Inc NASDAQ: AMAT has just crossed the price-to-sales valuation it held at the peak of the dot-com bubble in April 2000 might have been enough to get even the most committed bulls reaching for the Pepto.

Applied Materials Today

AMAT

Applied Materials

$578.88 -61.30 (-9.58%)

As of 02:51 PM Eastern

52-Week Range$154.46▼

$641.18Dividend Yield0.37%

P/E Ratio54.35

Price Target$501.26

That’s because headlines comparing a stock's valuation to its dot-com bubble level usually serve as a flashing red light for investors. When you consider just how big a tear the semiconductor equipment maker has been on, it’s somewhat understandable.

Get Applied Materials alerts:

Applied Materials’ share hit yet another fresh all-time high this week, as the multi-month rally continued to gain momentum. All told, the stock is up more than 140% year to date and a staggering 50% in the past month alone.

That kind of run is the kind that makes new highs, breaks technical models, and, eventually, attracts headlines like this one. The question for investors is whether that historical comparison is the warning sign it sounds like, or whether the current environment is different enough that the multiple is actually justified. Let's jump into it.

Why the Rally Is Anything But IrrationalThe starting point worth holding onto is that this isn't a 1999-style story of a company being bought purely on hope and hype. Applied Materials is genuinely benefiting from one of the most powerful structural tailwinds the semiconductor industry has ever seen. The team at Citi made that exact point earlier this week, raising its price target on the stock as it cited a "structural increase" in NAND demand driven by the explosion of agentic AI workloads.

The argument is technical, but still fairly intuitive when you boil it down. As AI workloads become more complex and demanding, they require a much larger memory pool than the fastest and most expensive memory types can practically provide. That's pushing the industry toward cheaper, higher-capacity alternatives, and Applied Materials sits at the heart of the equipment supply chain that makes those alternatives possible.

Coupled with ongoing innovation across the broader memory landscape, the team at Citi sees this shift as a structural tailwind that should continue to drive the company's earnings growth well into 2028. That's not a near-term sugar high. That's a multi-year trend that the bulls are betting will continue to drive revenue growth at rates most other tech stocks would kill for.

Analysts Are Unanimous in Their OutlookOverall MarketRank™82nd Percentile

Analyst RatingModerate Buy

Upside/Downside14.0% Downside

Short Interest LevelHealthy

Dividend StrengthModerate

News Sentiment1.12 Insider TradingSelling Shares

Proj. Earnings Growth31.90%

See Full Analysis

In fact, Applied Materials’ Moderate Buy consensus rating and the latest round of higher analyst price targets are another reason to avoid leaning too heavily on the dot-com comparison.

Citi’s $710 target, up from $550, still implies upside from recent highs, and the firm is far from alone.

Barclays, UBS Group and Cantor Fitzgerald are among the firms that have recently reiterated or raised bullish views on Applied Materials.

When well-regarded analysts continue to raise their targets, even after a stock has already gained 140% this year, it tells you something about their confidence in its growth trajectory.

The Risks Are Real TooFor all that, however, there's no escaping the sheer one-directional nature of the chart in recent months, or this week’s dot-com headline. Applied Materials’ relative strength index is also pushing into overbought territory, which can often set the scene for a sharp reset whenever sentiment starts swinging the other way.

There are also genuine fundamental concerns that shouldn't be ignored. Almost 30% of the company’s revenue comes from China, which leaves Applied Materials more exposed than most to any sudden trade-policy disruption or further restrictions on equipment exports.

How to Build a Position CarefullyFor investors looking to get involved, there’s plenty to consider. The bull case is genuine, the structural demand picture is compelling, and the analyst community is firmly in the camp of higher prices ahead. But the chart is also stretched, the valuation is at historically extreme levels, and one-directional rallies tend to find their reckoning eventually.

For investors looking to chase this entry, that probably means resisting the urge to go all-in on a single position and instead building it up in stages. A starter position now, with the discipline to add on the pullbacks that almost certainly lie ahead, is likely a smarter way to play this than trying to time the absolute top. The dot-com comparison may make for an uncomfortable headline, but the difference between 2000 and 2026 is that this time, the demand is genuinely there. The trick is to make sure you don't pay too much for it.

Should You Invest $1,000 in Applied Materials Right Now?Before you consider Applied Materials, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Applied Materials wasn't on the list.

While Applied Materials currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries.

"Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

The pick and shovels behind the AI trade are getting more favorable coverage from analysts, seen in Wells Fargo's price target hikes in ASML (ASML), Applied Materials (AMAT), KLA Corp. (KLAC), and Lam Research (LRCX). Marley Kayden walks investors through the analyst note and offers more insight on why firms are turning bullish on these names.

Applied Materials (AMAT - Free Report) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.

Shares of this maker of chipmaking equipment have returned +48.1% over the past month versus the Zacks S&P 500 composite's +0.1% change. The Zacks Electronics - Semiconductors industry, to which Applied Materials belongs, has gained 11.9% over this period. Now the key question is: Where could the stock be headed in the near term?

While media releases or rumors about a substantial change in a company's business prospects usually make its stock 'trending' and lead to an immediate price change, there are always some fundamental facts that eventually dominate the buy-and-hold decision-making.

Revisions to Earnings EstimatesHere at Zacks, we prioritize appraising the change in the projection of a company's future earnings over anything else. That's because we believe the present value of its future stream of earnings is what determines the fair value for its stock.

Our analysis is essentially based on how sell-side analysts covering the stock are revising their earnings estimates to take the latest business trends into account. When earnings estimates for a company go up, the fair value for its stock goes up as well. And when a stock's fair value is higher than its current market price, investors tend to buy the stock, resulting in its price moving upward. Because of this, empirical studies indicate a strong correlation between trends in earnings estimate revisions and short-term stock price movements.

For the current quarter, Applied Materials is expected to post earnings of $3.35 per share, indicating a change of +35.1% from the year-ago quarter. The Zacks Consensus Estimate remained unchanged over the last 30 days.

The consensus earnings estimate of $12.1 for the current fiscal year indicates a year-over-year change of +28.5%. This estimate has changed +0.7% over the last 30 days.

For the next fiscal year, the consensus earnings estimate of $15.96 indicates a change of +31.9% from what Applied Materials is expected to report a year ago. Over the past month, the estimate has changed +1.2%.

With an impressive externally audited track record, our proprietary stock rating tool -- the Zacks Rank -- is a more conclusive indicator of a stock's near-term price performance, as it effectively harnesses the power of earnings estimate revisions. The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #2 (Buy) for Applied Materials.

The chart below shows the evolution of the company's forward 12-month consensus EPS estimate:

12 Month EPS

Revenue Growth ForecastWhile earnings growth is arguably the most superior indicator of a company's financial health, nothing happens as such if a business isn't able to grow its revenues. After all, it's nearly impossible for a company to increase its earnings for an extended period without increasing its revenues. So, it's important to know a company's potential revenue growth.

In the case of Applied Materials, the consensus sales estimate of $8.98 billion for the current quarter points to a year-over-year change of +23%. The $33.29 billion and $41.74 billion estimates for the current and next fiscal years indicate changes of +17.3% and +25.4%, respectively.

Last Reported Results and Surprise HistoryApplied Materials reported revenues of $7.91 billion in the last reported quarter, representing a year-over-year change of +11.4%. EPS of $2.86 for the same period compares with $2.39 a year ago.

Compared to the Zacks Consensus Estimate of $7.69 billion, the reported revenues represent a surprise of +2.82%. The EPS surprise was +6.72%.

The company beat consensus EPS estimates in each of the trailing four quarters. The company topped consensus revenue estimates each time over this period.

ValuationNo investment decision can be efficient without considering a stock's valuation. Whether a stock's current price rightly reflects the intrinsic value of the underlying business and the company's growth prospects is an essential determinant of its future price performance.

While comparing the current values of a company's valuation multiples, such as price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), with its own historical values helps determine whether its stock is fairly valued, overvalued, or undervalued, comparing the company relative to its peers on these parameters gives a good sense of the reasonability of the stock's price.

The Zacks Value Style Score (part of the Zacks Style Scores system), which pays close attention to both traditional and unconventional valuation metrics to grade stocks from A to F (an A is better than a B; a B is better than a C; and so on), is pretty helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued.

Applied Materials is graded F on this front, indicating that it is trading at a premium to its peers. Click here to see the values of some of the valuation metrics that have driven this grade.

Bottom LineThe facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about Applied Materials. However, its Zacks Rank #2 does suggest that it may outperform the broader market in the near term.

NEW YORK, June 19, 2026 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Zoetis Inc. (NYSE: ZTS).

Shareholders who purchased shares of ZTS during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.

CONTACT US HERE:

https://securitiesclasslaw.com/securities/zoetis-inc-loss-submission-form-2/?id=188973&from=3 

CLASS PERIOD: January 14, 2025 to May 6, 2026

ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (i) veterinarian prescription growth and adoption of Zoetis’ Librela, a canine pain treatment, were sharply weakening as clinicians became more cautious following FDA safety warnings concerning serious neurological complications in dogs; (ii) Zoetis’ Simparica Trio was losing significant market share to a lower priced competing canine parasiticide with broader indicated use in a slowing overall market; and (iii) Zoetis’ dermatology products, Apoquel and Cytopoint, were losing substantial market share to a newly launched competing canine treatment.

DEADLINE: July 27, 2026 Shareholders should not delay in registering for this class action. Register your information here: https://securitiesclasslaw.com/securities/zoetis-inc-loss-submission-form-2/?id=188973&from=3 

NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of ZTS during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is July 27, 2026. There is no cost or obligation to you to participate in this case.

WHY GROSS LAW FIRM? The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a company lead to artificial inflation of the company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: [email protected] 
Phone: (646) 453-8903

Did you buy ZTS securities between January 14, 2025, and May 6, 2026?

Affected ZTS Investor Summary

Who: Zoetis Inc. (NYSE: ZTS) What: Securities fraud class action lawsuit filed Class Period: January 14, 2025 through May 6, 2026 Deadline to Seek Lead Plaintiff Status: Juy 27, 2026 Key Lawsuit Allegations: Material misstatements and/or omissions concerning the company's product adoption. Investor Action: Contact Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) for recovery options , /PRNewswire/ -- Kessler Topaz Meltzer & Check, LLP (www.ktmc.com), a nationally recognized securities litigation law firm, informs investors that a securities fraud class action lawsuit has been filed against Zoetis Inc. (Zoetis) (NYSE: ZTS) on behalf of those who purchased or otherwise acquired Zoetis securities between January 14, 2025 and May 6, 2026, inclusive (the "Class Period").  The lawsuit is filed in the United States District Court for the Southern District of New York and is captioned City of Ann Arbor Retiree Health Care Benefit Plan & Trust v. Zoetis Inc., No. 26-cv-04401 (S.D.N.Y.).  Investors have until July 27, 2026, to file for lead plaintiff status. 

CONTACT KTMC TO DISCUSS YOUR LEGAL RIGHTS:    
If you purchased or acquired Zoetis securities and have lost money on your investment, please provide your information here:

https://www.ktmc.com/zts-zoetis-inc-class-action-lawsuit?utm_source=PR_Newswire&utm_medium=pressrelease&utm_campaign=zts&mktm=PR

You can also contact attorney Jonathan Naji, Esq. by calling (484) 270-1453 or by email at [email protected].  There is no cost or obligation to speak with an attorney.

ZOETIS INC. CLASS ACTION LAWSUIT - COMPLAINT ALLEGATION SUMMARY:
Zoetis is an animal health company that develops, manufactures, and sells vaccines, medications, diagnostics, and more for companion and livestock animals.

The complaint alleges that, throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material facts about the company's business, operations, and prospects. Specifically, Defendants misrepresented and/or failed to disclose that: (1) prescription growth and use of Librela, a pain treatment for dogs, was weakening following FDA safety warnings of serious neurological complications; (2) Simparica Trio, a preventative for fleas, ticks, and heartworm, was losing significant market share to a lower priced competitor; (3) the company's dermatological products, specifically Apoquel and Cytopoint, were also losing market share to competition; and (4) as a result of the foregoing, Defendants' statements about the company's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Why did Zoetis's Stock Drop?
On May 7, 2026, Zoetis reported its 2026 first quarter financial results which showed significant decline across its Companion Animal business. On this news, Zoetis's stock price fell 21.5%.

WHAT ZTS INVESTORS CAN DO NOW:

File to be lead plaintiff by July 27, 2026. Contact KTMC for a free case evaluation. All representation is on a contingency fee basis, there is no cost to you. Retain counsel of choice or take no action. THE LEAD PLAINTIFF PROCESS FOR ZOETIS INC. INVESTORS:
Zoetis investors may, no later than July 27, 2026, seek to be appointed as a lead plaintiff representative of the class through Kessler Topaz Meltzer & Check, LLP or other counsel, or may choose to do nothing and remain an absent class member. A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation.  The lead plaintiff is usually the investor or small group of investors who have the largest financial interest and who are also adequate and typical of the proposed class of investors. The lead plaintiff selects counsel to represent the lead plaintiff and the class and these attorneys, if approved by the court, are lead or class counsel. Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff.

Kessler Topaz Meltzer & Check, LLP encourages Zoetis investors to contact the firm for more information.

ABOUT KESSLER TOPAZ MELTZER & CHECK, LLP (KTMC):    
Kessler Topaz Meltzer & Check, LLP (KTMC) is a leading U.S. plaintiff-side law firm focused on securities-fraud class actions and global investor protection. The firm represents individual investors as well as institutions, such as major pension funds, asset managers, and international investors. KTMC has led some of the largest recoveries in securities litigation and has been recognized by peers and the legal media with numerous accolades, including The National Law Journal's Plaintiff's Hot List and Trailblazers in Plaintiffs' Law, BTI Consulting Group's Honor Roll of Most Feared Law Firms, The Legal Intelligencer's Class Action Firm of the Year, Lawdragon's Leading Plaintiff Financial Lawyers, and Law360's Titans of the Plaintiffs Bar.  The firm operates globally with offices in Pennsylvania and California.  KTMC has recovered over $25 billion for our clients and the classes they represent.  For more information about Kessler Topaz Meltzer & Check, LLP, please visit www.ktmc.com.  The complaint in this matter was not filed by KTMC.

CONTACT:
Jonathan Naji, Esq.
(484) 270-1453
280 King of Prussia Road
Radnor, PA 19087
[email protected]

May be considered attorney advertising in certain jurisdictions.  Past results do not guarantee future outcomes.

SOURCE Kessler Topaz Meltzer & Check, LLP

, /PRNewswire/ --

Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Zoetis Inc. (NYSE: ZTS) between January 14, 2025 and May 6, 2026, inclusive (the "Class Period"), of the important July 27, 2026 lead plaintiff deadline.

So What: If you purchased Zoetis securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

What to do next: To join the Zoetis class action, go to https://rosenlegal.com/cases/zoetis-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than July 27, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

Details of the case: According to the lawsuit, throughout the Class Period, defendants made false and/or misleading statements and touted growing market share, strong veterinarian adoption, and accelerating sales growth across Zoetis' flagship Companion Animal products and/or failed to disclose that: (1) veterinarian prescription growth and adoption of Zoetis' Librela, a canine pain treatment, were sharply weakening as clinicians became more cautious following FDA safety warnings concerning serious neurological complications in dogs; (2) Zoetis' Simparica Trio was losing significant market share to a lower priced competing canine parasiticide with broader indicated use in a slowing overall market; and (3) Zoetis' dermatology products, Apoquel and Cytopoint, were losing substantial market share to a newly launched competing canine treatment. When the true details entered the market, the lawsuit claims that investors suffered damages. 

To join the Zoetis class action, go to https://rosenlegal.com/cases/zoetis-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

     Laurence Rosen, Esq.
     Phillip Kim, Esq.
     The Rosen Law Firm, P.A.
     275 Madison Avenue, 40th Floor
     New York, NY 10016
     Tel: (212) 686-1060
     Toll Free: (866) 767-3653
     Fax: (212) 202-3827
     [email protected]
     www.rosenlegal.com

SOURCE THE ROSEN LAW FIRM, P. A.

New York, New York--(Newsfile Corp. - June 21, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Zoetis Inc. (NYSE: ZTS) and certain of its officers.

This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Zoetis securities between January 14, 2025 and May 6, 2026, both dates inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: bgandg.com/ZTS.

Zoetis Case Details

The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements concerning the growth, competitive positioning, market share, and veterinarian adoption of key products within the Companion Animal segment while failing to disclose that:

veterinarian prescription growth and adoption of Zoetis' Librela, a canine pain treatment, were sharply weakening as clinicians became more cautious following FDA safety warnings concerning serious neurological complications in dogs; Zoetis' Simparica Trio was losing significant market share to a lower-priced competing canine parasiticide with broader indicated use in a slowing overall market; and Zoetis' dermatology products, Apoquel and Cytopoint, were losing substantial market share to a newly launched competing canine treatment.What's Next for Zoetis Investors?

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm's site: bgandg.com/ZTS, or you may contact Peretz Bronstein, Esq. or his Client Relations Manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC at 917-590-0911. If you suffered a loss in Zoetis you have until July 27, 2026, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as lead plaintiff.

No Cost to Zoetis Investors

We, Bronstein, Gewirtz & Grossman LLC, represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.

Why Bronstein, Gewirtz & Grossman, LLC for Zoetis Securities Class Action?

Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide. More at www.bgandg.com

"Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace," said Peretz Bronstein, Founding Partner of Bronstein, Gewirtz & Grossman, LLC.

Follow us for updates on LinkedIn, X, Facebook, or Instagram.

Attorney advertising.
Prior results do not guarantee similar outcomes.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/299273

Source: Bronstein, Gewirtz & Grossman, LLC

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

, /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Zoetis Inc. ("Zoetis" or "the Company") (NYSE: ZTS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Investors who purchased the Company's securities between January 14, 2025 and May 6, 2026, inclusive (the "Class Period"), are encouraged to contact the firm before July 27, 2026.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at [email protected].

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, the Company made false and misleading statements to the market. Zoetis suffered from weakening veterinarian prescription growth for its Librela medication after the FDA issued safety warnings about neurological complications in dogs. The Company's Trio product lost market share to competitors. The Company's Apoquel and Cytopoint dermatology products lost market share to newly launched competing treatments for dogs. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about Zoetis, investors suffered damages.

Join the case to recover your losses

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.             

CONTACT:

The Schall Law Firm
Brian Schall, Esq.,
www.schallfirm.com
Office: 310-301-3335
[email protected]

SOURCE The Schall Law Firm

Long-term investing is about building your portfolio brick by brick. That could mean adding money weekly, monthly, or whenever you have extra cash on hand. How much you can invest at a time is all relative, but $1,000 is a nice round number. If you had that much to put into the market, where would you look?

Evergreen sectors are always a great starting point. These are industries that never go out of style. Take healthcare stocks, for example. People will always need care, and there's always a push to innovate and develop better ways to provide it.

It's also a massive market. The United States racked up nearly $5.3 trillion in healthcare spending in 2024. That number has risen steadily for decades, and there's little reason to think it won't continue to rise. In other words, healthcare remains an excellent industry in which to invest your capital.

Here's why CRISPR Therapeutics (CRSP 0.63%), Zoetis (ZTS +0.99%), and Danaher (DHR +0.09%) are arguably the best stocks you can buy with $1,000 right now.

Image source: The Motley Fool.

1. A promising growth stock packed with long-term upside CRISPR Therapeutics is a textbook example of healthcare innovation. The company is an emerging leader in CRISPR genome editing, the science of editing a patient's DNA and reintroducing it into their body to treat various cancers, diseases, and other conditions that traditional pharmaceuticals cannot treat.

The company co-developed Casgevy, a one-time treatment for sickle cell disease, with Vertex Pharmaceuticals. It's CRISPR Therapeutics' first product to receive U.S. Food and Drug Administration (FDA) approval. Commercialization is still slowly ramping up, which has made CRISPR stock a bit volatile this year. Shares currently trade in the low end of their 52-week range.

Today's Change

(

-0.63

%) $

-0.34

Current Price

$

54.02

The biotech has four other treatments undergoing clinical trials, including Zugocaptagene Geleucel, an experimental CAR-T therapy for cancer.

CRISPR's market value of $5.1 billion feels pricey given that analysts expect only $36 million in sales this fiscal year, but growth can happen in spurts, especially with another pipeline success. Analysts currently expect the company's sales to soar to $145 million next fiscal year as it continues to sell Casgevy.

2. An oversold animal health leader Zoetis is a leading animal health company with a broad range of medicines, vaccines, and diagnostic products for livestock and companion animals. Animal health is a lucrative niche with long-term growth potential. Demand for animal proteins should continue to rise as the global population grows and emerging economies steadily mature. Younger Americans are also spending more money on pets than previous generations, another good sign for Zoetis moving forward.

Wall Street has hammered the stock over the past couple of years. Librela, a monoclonal antibody treatment for osteoarthritis (OA) pain in canines, sparked controversy due to links to severe side effects and animal deaths. Consumers brought a class action lawsuit against Zoetis. Although a judge ultimately dismissed the lawsuit, the terrible publicity has crushed Librela's sales. People pulling back on vet visits has also dragged on business.

Today's Change

(

0.99

%) $

0.75

Current Price

$

76.64

At this point, Zoetis has fallen to just 11 times 2026 earnings estimates. Consider that Zoetis has typically traded at a price-to-earnings (P/E) ratio of 37 over the past decade, and analysts still expect the company to grow earnings by an average of 9% annually over the next three to five years. The selling seems way overdone at this point, positioning the stock for strong returns going forward.

3. A proven compounder with more upside left Danaher owns several biotech, diagnostics, and life sciences businesses, making it a key partner for healthcare's most innovative companies. The stock has returned more than 30,000% over the past few decades, outperforming the broader stock market by a mile.

But that's the past. Danaher stock is currently down 40% from its high roughly two years ago. The company has dealt with a bit of a post-pandemic hangover. COVID-19 vaccine development boosted sales, but that dropped off.

Mergers and acquisitions are a big part of Danaher's identity, and management is tapping that to try to spark growth again. Danaher closed its $9.9 billion acquisition of Masimo earlier this month. Masimo is a leader in pulse oximetry technology, which measures the oxygen levels in your blood. The company has a strong presence in hospitals, giving Danaher's diagnostics business a potential shot in the arm.

Today's Change

(

0.09

%) $

0.16

Current Price

$

178.35

Danaher's slide values the stock at approximately 21 times its 2026 earnings estimates, and analysts expect the company to grow earnings by an average of 9% over the next three to five years. No, the past doesn't guarantee the future. That said, it's hard not to like this legendary market-beating healthcare stock with a P/E in the low 20s.

LOS ANGELES, June 22, 2026 (GLOBE NEWSWIRE) -- Glancy Prongay Wolke & Rotter LLP reminds investors of the upcoming July 27, 2026 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Zoetis Inc. (“Zoetis” or the “Company”) (NYSE: ZTS) securities between January 14, 2025 and May 6, 2026, inclusive (the “Class Period”).

IF YOU SUFFERED A LOSS ON YOUR ZOETIS INVESTMENTS, CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS UNDER THE FEDERAL SECURITIES LAWS.

What Happened?
On August 5, 2025, Zoetis released its second quarter 2025 financial results, reporting weakened demand trends within its Companion Animal portfolio.

On this news, Zoetis’ stock price fell $5.69, or 3.8%, to close at $146.12 per share on August 5, 2025, thereby injuring investors.

Then, on November 4, 2025, Zoetis released its third quarter 2025 financial results, revealing slowed growth across its key Companion Animal franchises and disclosing continued weakness in sales of its canine pain treatment, Librela, and increased competitive pressure in dermatology and parasiticides. The Company also lowered its full year sales outlook.

On this news, Zoetis’ stock price fell $19.89, or 13.8%, to close at $124.46 per share on November 4, 2025.

Then, on May 7, 2026, Zoetis released its first quarter 2026 financial results, reporting slowing overall revenue growth, declining Companion Animal sales performance, and worsening results across its key dermatology and parasiticides franchises, stating that “competition intensified across key pet care categories, including dermatology and parasiticides,” that “pet owners demonstrated increased price sensitivity,” and that “these new entrants have not yet translated into overall market expansion.”

The Company also explained that “price has played a larger role in the decision process,” that “[s]hare loss is being amplified by a derm market with declining patient volume in the clinic,” and that contraction in the parasiticides market was negatively impacting prescription volumes and compliance. In addition, the Company admitted that it was operating in “a more price sensitive and competitive environment” and further reduced its 2026 growth outlook based on continuing competitive and operating pressures.

On this news, Zoetis’ stock price fell $23.91, or 21.5%, to close at $87.31 per share on May 7, 2026, thereby injuring investors further.

What Is The Lawsuit About?
The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) veterinarian prescription growth and adoption of Zoetis’ Librela, a canine pain treatment, were sharply weakening as clinicians became more cautious following FDA safety warnings concerning serious neurological complications in dogs; (2) Zoetis’ Simparica Trio was losing significant market share to a lower priced competing canine parasiticide with broader indicated use in a slowing overall market; and (3) Zoetis’ dermatology products, Apoquel and Cytopoint, were losing substantial market share to a newly launched competing canine treatment; and (4) as a result, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.

If you purchased or otherwise acquired Zoetis securities during the Class Period, you may move the Court no later than July 27, 2026 to request appointment as lead plaintiff in this putative class action lawsuit.

Contact Us To Participate or Learn More:
If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us:
Charles Linehan, Esq.,
Glancy Prongay Wolke & Rotter LLP,
1925 Century Park East, Suite 2100,
Los Angeles California 90067
Email: [email protected]
Telephone: 310-201-9150,
Toll-Free: 888-773-9224
Visit our website at www.glancylaw.com.
Follow us for updates on LinkedIn, Twitter, or Facebook.

If you inquire by email, please include your mailing address, telephone number and number of shares purchased.

To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contact Us:
Glancy Prongay Wolke & Rotter LLP,
1925 Century Park East, Suite 2100
Los Angeles, CA 90067
Charles Linehan
Email: [email protected]
Telephone: 310-201-9150
Toll-Free: 888-773-9224
Visit our website at: www.glancylaw.com.

NEW YORK, June 22, 2026 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Zoetis Inc. (NYSE: ZTS) between January 14, 2025 and May 6, 2026, inclusive (the “Class Period”), of the important July 27, 2026 lead plaintiff deadline.

SO WHAT: If you purchased Zoetis securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Zoetis class action, go to https://rosenlegal.com/cases/zoetis-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than July 27, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants made false and/or misleading statements and touted growing market share, strong veterinarian adoption, and accelerating sales growth across Zoetis’ flagship Companion Animal products and/or failed to disclose that: (1) veterinarian prescription growth and adoption of Zoetis’ Librela, a canine pain treatment, were sharply weakening as clinicians became more cautious following FDA safety warnings concerning serious neurological complications in dogs; (2) Zoetis’ Simparica Trio was losing significant market share to a lower priced competing canine parasiticide with broader indicated use in a slowing overall market; and (3) Zoetis’ dermatology products, Apoquel and Cytopoint, were losing substantial market share to a newly launched competing canine treatment. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Zoetis class action, go to https://rosenlegal.com/cases/zoetis-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

Contact Information:

        Laurence Rosen, Esq.
        Phillip Kim, Esq.
        The Rosen Law Firm, P.A.
        275 Madison Avenue, 40th Floor
        New York, NY 10016
        Tel: (212) 686-1060
        Toll Free: (866) 767-3653
        Fax: (212) 202-3827
        [email protected]
        www.rosenlegal.com

NEW YORK, June 23, 2026 (GLOBE NEWSWIRE) -- IMPORTANT DATE: July 27, 2026. Investors who purchased Zoetis Inc. (NYSE: ZTS) securities between January 14, 2025 and May 6, 2026 and wish to seek appointment as lead plaintiff must file a motion with the Court by this date. Start your claim now before the deadline. You may also contact Joseph E. Levi, Esq. at [email protected] or (888) SueWallSt.

Zoetis shares declined from $151.81 before the first revelation to $87.31 following the fourth corrective disclosures. A securities class action is pending in the United States District Court for the Southern District of New York.

What Is a Lead Plaintiff?

Under the Private Securities Litigation Reform Act of 1995, the Court appoints a lead plaintiff to represent the interests of all class members. In the Zoetis case, lead plaintiff applicants must demonstrate losses from purchases of ZTS securities between January 14, 2025 and May 6, 2026. The lead plaintiff selects counsel, oversees litigation strategy, and approves any settlement on behalf of the class.

Lead Plaintiff Facts

The lead plaintiff is typically the investor or group with the largest financial interest in the caseThere is no minimum loss requirement to apply for lead plaintiff statusServing as lead plaintiff does not require out-of-pocket payment; attorneys work on contingencyLead plaintiffs are not required to attend trial or give testimony in the vast majority of casesInvestors who do not seek lead plaintiff status remain absent class members and may still participate in any recoveryThe July 27, 2026 deadline applies only to lead plaintiff motions, not to class membership Post-Deadline Procedures

After July 27, 2026, the Court will review competing motions and appoint a lead plaintiff based on the adequacy and typicality of the applicant's claims and the size of the applicant's financial stake. The appointed lead plaintiff will then select lead counsel, and the case will proceed through discovery, class certification, and potentially trial or settlement.

Find out if you qualify to recover losses or call (888) SueWallSt.

About the Zoetis Class Action

The action alleges Zoetis and certain officers made materially false and misleading statements regarding the Company's Companion Animal product portfolio, concealing safety concerns with Librela, competitive losses in parasiticides and dermatology, and declining veterinarian confidence. Four corrective disclosures between August 2025 and May 2026 allegedly removed artificial inflation from ZTS shares.

"The lead plaintiff process is designed to ensure the class is represented by shareholders with substantial interests in the outcome of the litigation. Investors with losses in Zoetis during the Class Period should evaluate whether seeking appointment serves their interests before the July 27 deadline." -- Joseph E. Levi, Esq.

SueWallSt | Top 50 Securities Firm | (888) SueWallSt | www.zlk.com

Frequently Asked Questions About the ZTS Lawsuit

Q: What is the ZTS lead plaintiff deadline? A: The deadline to apply for lead plaintiff appointment is July 27, 2026. This deadline applies only to investors seeking to serve as lead plaintiff. Class members who do not apply may still participate in any recovery without taking action before this date.

Q: What is a lead plaintiff and why does it matter? A: A lead plaintiff is the investor appointed by the court to represent the entire class. Lead plaintiffs are typically investors with the largest documented losses. Being appointed does not increase individual recovery but gives direct oversight of how the case is run.

Q: What if I missed the lead plaintiff deadline? A: The deadline applies only to investors seeking lead plaintiff appointment. Class members who miss it can still participate in any settlement or recovery.

Q: What does it cost me to participate? A: Nothing. Securities class actions are handled on a pure contingency basis. No upfront fees, no retainer, no out-of-pocket costs.

Q: What documents do I need to make a claim? A: Brokerage statements or trade confirmations showing purchase dates, share quantities, prices paid, and any subsequent sale dates and prices.

Q: How long will the lawsuit take to resolve? A: Securities class actions typically take two to four years from initial filing to resolution.

CONTACT:
SueWallSt
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
[email protected]
Tel: (888) SueWallSt
Fax: (212) 363-7171

Did you buy ZTS securities between January 14, 2025, and May 6, 2026?

Affected ZTS Investor Summary

Who: Zoetis Inc. (NYSE: ZTS)What: Securities fraud class action lawsuit filedClass Period: January 14, 2025 through May 6, 2026Deadline to Seek Lead Plaintiff Status: Juy 27, 2026Key Lawsuit Allegations: Material misstatements and/or omissions concerning the company’s product adoption.Investor Action: Contact Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) for recovery options RADNOR, Pa., June 23, 2026 (GLOBE NEWSWIRE) -- Kessler Topaz Meltzer & Check, LLP (www.ktmc.com), a nationally recognized securities litigation law firm, informs investors that a securities fraud class action lawsuit has been filed against Zoetis Inc. (Zoetis) (NYSE: ZTS) on behalf of those who purchased or otherwise acquired Zoetis securities between January 14, 2025 and May 6, 2026, inclusive (the “Class Period”). The lawsuit is filed in the United States District Court for the Southern District of New York and is captioned City of Ann Arbor Retiree Health Care Benefit Plan & Trust v. Zoetis Inc., No. 26-cv-04401 (S.D.N.Y.). Investors have until July 27, 2026, to file for lead plaintiff status.

CONTACT KTMC TO DISCUSS YOUR LEGAL RIGHTS:
If you purchased or acquired Zoetis securities and have lost money on your investment, please provide your information here:

https://www.ktmc.com/zts-zoetis-inc-class-action-lawsuit?utm_source=Globe&utm_medium=pressrelease&utm_campaign=zts&mktm=PR

You can also contact attorney Jonathan Naji, Esq. by calling (484) 270-1453 or by email at [email protected]. There is no cost or obligation to speak with an attorney.

ZOETIS INC. CLASS ACTION LAWSUIT - COMPLAINT ALLEGATION SUMMARY:
Zoetis is an animal health company that develops, manufactures, and sells vaccines, medications, diagnostics, and more for companion and livestock animals.

The complaint alleges that, throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material facts about the company’s business, operations, and prospects. Specifically, Defendants misrepresented and/or failed to disclose that: (1) prescription growth and use of Librela, a pain treatment for dogs, was weakening following FDA safety warnings of serious neurological complications; (2) Simparica Trio, a preventative for fleas, ticks, and heartworm, was losing significant market share to a lower priced competitor; (3) the company’s dermatological products, specifically Apoquel and Cytopoint, were also losing market share to competition; and (4) as a result of the foregoing, Defendants’ statements about the company’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Why did Zoetis’s Stock Drop?
On May 7, 2026, Zoetis reported its 2026 first quarter financial results which showed significant decline across its Companion Animal business. On this news, Zoetis’s stock price fell 21.5%.

WHAT ZTS INVESTORS CAN DO NOW:

File to be lead plaintiff by July 27, 2026.Contact KTMC for a free case evaluation. All representation is on a contingency fee basis, there is no cost to you.Retain counsel of choice or take no action. THE LEAD PLAINTIFF PROCESS FOR ZOETIS INC. INVESTORS:
Zoetis investors may, no later than July 27, 2026, seek to be appointed as a lead plaintiff representative of the class through Kessler Topaz Meltzer & Check, LLP or other counsel, or may choose to do nothing and remain an absent class member. A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation. The lead plaintiff is usually the investor or small group of investors who have the largest financial interest and who are also adequate and typical of the proposed class of investors. The lead plaintiff selects counsel to represent the lead plaintiff and the class and these attorneys, if approved by the court, are lead or class counsel. Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff.

Kessler Topaz Meltzer & Check, LLP encourages Zoetis investors to contact the firm for more information.

ABOUT KESSLER TOPAZ MELTZER & CHECK, LLP (KTMC):

Kessler Topaz Meltzer & Check, LLP (KTMC) is a leading U.S. plaintiff-side law firm focused on securities-fraud class actions and global investor protection. The firm represents individual investors as well as institutions, such as major pension funds, asset managers, and international investors. KTMC has led some of the largest recoveries in securities litigation and has been recognized by peers and the legal media with numerous accolades, including The National Law Journal’s Plaintiff’s Hot List and Trailblazers in Plaintiffs' Law, BTI Consulting Group’s Honor Roll of Most Feared Law Firms, The Legal Intelligencer’s Class Action Firm of the Year, Lawdragon’s Leading Plaintiff Financial Lawyers, and Law360’s Titans of the Plaintiffs Bar. The firm operates globally with offices in Pennsylvania and California. KTMC has recovered over $25 billion for our clients and the classes they represent. For more information about Kessler Topaz Meltzer & Check, LLP, please visit www.ktmc.com. The complaint in this matter was not filed by KTMC.

CONTACT:

Jonathan Naji, Esq.
(484) 270-1453
280 King of Prussia Road
Radnor, PA 19087
[email protected]

May be considered attorney advertising in certain jurisdictions. Past results do not guarantee future outcomes.

Elevance Health (NYSE: ELV) today announced it has invested $640 million in affordable housing over the past five years, building on more than $1 billion invested over nearly two decades. These investments reflect the company’s continued commitment to addressing social drivers of health, helping lower the total cost of care, and expanding access to safe, stable, and affordable housing.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260617980738/en/

Elevance Health has invested more than $1 billion across approximately 400 properties, supporting more than 40,000 housing units in 45 states, the District of Columbia, Puerto Rico, and Guam.

Over the past five years, Elevance Health has invested $640 million across 15 properties, supporting the development of 2,654 affordable housing units, including apartment homes, townhomes, and single-family residences, across 10 states. In total, the company has invested more than $1 billion across approximately 400 properties, supporting more than 40,000 housing units in 45 states, the District of Columbia, Puerto Rico, and Guam.

“Access to safe and stable housing is fundamental to improving health outcomes and building stronger communities,” said Aimée K. Dailey, president of Government Health Benefits at Elevance Health. “Our continued investment reflects a long-term commitment to addressing the underlying factors that impact overall health. By focusing on high-impact housing initiatives and strong local partnerships, we are helping individuals and families achieve stability, improve their health, reduce avoidable healthcare costs, and create a foundation for long-term wellbeing.”

A National Commitment to Whole Health and Medicaid Populations

Housing instability remains one of the most pressing challenges impacting health outcomes across the United States. According to the U.S. Department of Housing and Urban Development, more than 653,000 people experienced homelessness in 2023, including families with children, reflecting the growing housing challenges facing communities nationwide. For many individuals, the lack of stable housing creates significant barriers to accessing care and managing health conditions.

Elevance Health’s approach is grounded in its whole health strategy, which recognizes that social and environmental factors play a significant role in health outcomes. Housing is one of the most critical of these factors, particularly for Medicaid populations.

Internal analysis of Elevance Health-affiliated Medicaid plan members with high healthcare utilization found that 43 percent of members with more than 50 emergency room visits per year were experiencing homelessness. This underscores the direct connection between housing instability and avoidable healthcare utilization.

By investing in affordable housing and supportive services, Elevance Health is helping to address these challenges early and support better outcomes for the individuals and communities it serves.

These investments reflect an evolution toward more targeted, high-impact housing developments that enable deeper community partnerships and more measurable outcomes at the local level.

Expanding Access to Stable Housing for Vulnerable Populations

Affordable housing plays a critical role in supporting low- to moderate-income individuals and families, including seniors, people with disabilities, and individuals experiencing or at risk of homelessness. These developments are typically designed for households earning 80 percent or less of the area median income and help ensure residents spend no more than 30 percent of their income on housing, reducing financial strain and improving overall stability.

Elevance Health’s investments are designed to support populations with complex needs, including individuals living with intellectual and or developmental disabilities, seniors on fixed incomes, and families facing housing insecurity.

Stable housing is closely linked to improved health outcomes. Individuals with access to affordable housing are more likely to experience fewer potentially costly emergency room visits and hospitalizations, better manage chronic conditions such as diabetes, asthma, and hypertension, maintain consistent access to preventive and primary care, and achieve improved mental health outcomes.

Conversely, housing instability is associated with higher rates of chronic illness, increased healthcare utilization, and poorer overall health outcomes. Even frequent moves can negatively impact health. Children who move multiple times within a year are more likely to experience chronic conditions and disruptions in care.

Delivering Innovative, Community-Based Housing Solutions

Elevance Health works through its affiliated health plans to connect members to housing resources and services that help prevent homelessness and support long-term stability.

Across its Medicaid plans, Elevance Health supports housing programs that address barriers such as past-due rent, utility costs, and move-in expenses. Flexible funding programs help members remain housed by covering essential needs such as security deposits, overdue rent, and utility bills. These programs also connect members with housing coordinators who work directly with individuals and families to identify solutions and navigate available resources.

In one example, flexible housing support programs have assisted approximately 1,500 households across multiple states by helping cover rent, utilities, and other essential housing-related expenses.

Elevance Health also collaborates with community-based organizations, housing authorities, and local partners to help members access housing vouchers, prevent evictions, and secure stable housing that meets their needs. These partnerships are critical to ensuring that housing solutions are tailored to the unique needs of each community.

Integrating Health and Community-Based Support

In addition to supporting housing development, Elevance Health works to integrate health and social support services within communities wherever possible.

In select markets, this includes access to healthcare and wellness programs, care coordination for individuals with complex needs, behavioral health support, and connections to food, transportation, and other essential services.

These efforts help remove barriers to care and support individuals in managing their health more effectively. Programs that combine housing support with health and social services have demonstrated strong outcomes. In one state-based program, more than 90 percent of participating members maintained stable housing six months after receiving support.

“Affordable housing is a critical foundation for improving quality of life and strengthening communities,” said Dr. Adrienne McFadden, chief medical officer of Government Health Benefits at Elevance Health. “By working alongside community partners and aligning housing with health services, we are helping to create sustainable solutions that improve outcomes and support long-term stability.”

Looking Ahead

Elevance Health’s investments in affordable housing directly support state and community priorities, including improving population health and reducing avoidable healthcare costs.

The company and its affiliated health plans will continue to expand its affordable housing efforts across the country, aligning investments with community needs and opportunities to improve health outcomes at scale. Through this work, the company remains focused on building healthier communities and advancing its mission to improve lives and make healthcare simpler.

About Elevance Health

Elevance Health is a lifetime, trusted health partner whose purpose is to improve the health of humanity. The company supports consumers, families, and communities across the entire healthcare journey – connecting them to the care, support, and resources they need to lead better lives. Elevance Health’s companies serve approximately 105 million consumers through a diverse portfolio of industry-leading medical, pharmacy, behavioral, clinical, home health, and complex care solutions. For more information, please visit www.elevancehealth.com or follow us @ElevanceHealth on X and Elevance Health on LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260617980738/en/

Key Takeaways Elevance Health invested $640M in affordable housing over five years, supporting 2,654 units in 10 states.The strategy pairs housing with healthcare and support services for vulnerable Medicaid and Medicare members.Elevance says stable housing may improve outcomes, manage costs and support long-term growth. Elevance Health, Inc. (ELV - Free Report) recently announced that it has invested $640 million in affordable housing projects over the past five years, reinforcing its broader effort to address social factors that influence health outcomes. The investments supported the development of 2,654 affordable housing units across 15 properties in 10 states, including apartment homes, townhomes and single-family residences. The latest commitment brings ELV's total affordable housing investment to more than $1 billion over nearly two decades, ultimately supporting over 40,000 units across 45 states.

The initiative goes beyond building affordable housing. Elevance aims to pair housing with healthcare and community support services, particularly for vulnerable populations. The company believes that stable housing can improve health outcomes, increase access to care and help address social factors that often lead to poorer health. By helping high-risk Medicaid and Medicare members secure reliable housing, Elevance hopes to create healthier communities and improve member well-being.

The investment also aligns with Elevance's broader strategy of managing healthcare costs while improving member outcomes. For the first quarter of 2026, the company reported adjusted earnings per share of $12.58 and raised its full-year adjusted EPS guidance. As healthcare utilization remains elevated across government-sponsored programs, addressing the root causes of poor health could help moderate medical costs and support long-term margin stability.

The announcement signals a long-term value creation strategy rather than an immediate earnings catalyst. These community-focused investments could strengthen Elevance's relationships with state agencies and enhance its position when competing for government-sponsored healthcare contracts. Overall, the initiative reflects management's focus on sustainable growth and long-term shareholder value.

ELV’s Stock Price PerformanceShares of Elevance Health have gained 11.6% year to date compared to the industry’s 6.5% decline over the same period.

Image Source: Zacks Investment Research

ELV’s Zacks Rank & Key PicksElevance Health currently carries a Zacks Rank #3 (Hold).

Some better-ranked stocks in the broader Medical space are Surgery Partners, Inc. (SGRY - Free Report) , BrightSpring Health Services, Inc. (BTSG - Free Report) and Alignment Healthcare, Inc. (ALHC - Free Report) , each sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.

The Zacks Consensus Estimate for Surgery Partners’ 2026 earnings is pegged at 36 cents per share, which has witnessed three upward revisions in the past 60 days, with no movement in the opposite direction. The consensus estimate for SGRY’s 2026 revenues is pinned at $3.41 billion, implying 3% year-over-year growth.

The Zacks Consensus Estimate for BrightSpring Health’s 2026 earnings is pegged at $1.67 per share, which has witnessed five upward revisions in the past 60 days, with no movement in the opposite direction. BTSG beat earnings estimates in three of the trailing four quarters and missed once, with the average surprise being 14.6%. The consensus estimate for 2026 revenues is pinned at $15.05 billion, implying 16.6% year-over-year growth.

The Zacks Consensus Estimate for Alignment Healthcare’s 2026 earnings is pegged at 20 cents per share, which has witnessed four upward revisions in the past 60 days, with no movement in the opposite direction. ALHC beat earnings estimates in each of the trailing four quarters, with the average surprise being 198.8%. The consensus estimate for 2026 revenues is pinned at $5.19 billion, implying 31.4% year-over-year growth.

While the Federal Reserve works out how to stop rampant inflation, consumers need to figure out how to make their dollars work harder for them at the store. In general, inflation works against retailers as shoppers pull back on spending, but some retailers actually benefit from it; off-price or discount retailers often report their best performance when everyone is looking for a deal.

That's why TJX Companies (TJX +0.47%) and Costco Wholesale (COST +0.90%) are some of the best stocks to own when times are tough. Here's why they can keep winning in the second half of the year.

Image source: Getty Images.

1. TJX Companies TJX is the umbrella company for TJ Maxx, Marshalls, HomeGoods, and Sierra, as well as many international off-price retail chains. It buys overstock and post-season merchandise, and shoppers love its great prices year-round, as well as the treasure-hunt feel of the stores, which keep them coming back as new merchandise arrives. The company owns more than 5,000 stores in 10 countries and has six e-commerce sites, providing a diversified backdrop to drive sales.

High-inflation periods bring in extra business as shoppers have less to spend and want the most bang for their buck. While many retailers are feeling the pinch and reporting pressured sales, TJX has demonstrated healthy growth.

Sales were up 9% year over year in the 2027 fiscal first quarter (ended May 2), with comparable sales (comps) up 6%. Earnings per share (EPS) increased 29% to $1.29. All divisions had increased comps and transactions, and management raised full-year guidance.

Today's Change

(

0.47

%) $

0.78

Current Price

$

164.95

CEO Ernie Herrman said, "Availability of quality, branded merchandise is outstanding." He expects the model to continue working for the foreseeable future and the company to capture market share long-term.

In previous challenging economies, TJX also outperformed, creating a hedge against the market, and TJX stock has outperformed the market over time. It also pays a growing dividend that yields 1% at the current price, providing another benefit for shareholders.

2. Costco Costco is the ultimate inflation stock. Its rock-bottom prices attract high volume, driving increased sales, higher profits, strong renewal rates, and new members.

CEO Ron Vachris said, "Our goal is to be the first to lower prices and last to raise them." Costco is taking a preemptive approach, lowering prices on some staples, like eggs, to provide greater value for its members and anticipate lower prices.

Costco has been reporting its highest growth in years as customers flock to its warehouses. Sales increased 11.6% year over year in the 2026 fiscal third quarter (ended May 10), and comps were up 9.8%. E-commerce remains a standout growth driver, and digitally enabled sales rose 21.5% in the quarter. Despite higher costs, profitability remained strong, and EPS increased from $4.28 last year to $4.93 this year.

Today's Change

(

0.90

%) $

8.56

Current Price

$

959.91

While higher oil prices have been negatively affecting many companies, Costco's lower gas prices are turning lemons into lemonade and bringing in new business. Since customers who fill up at its gas stations tend to spend more overall, this is another growth driver.

The best part is that Costco still has a long growth runway. It owns only 639 stores in the U.S. and isn't even in every state, and internationally, it's just getting started. Its long-term goal is to open 30 stores annually, and each of Costco's massive stores converts at high rates, providing a healthy path for long-term growth.

Costco stock also pays a growing dividend that yields 0.6% at the current price, and it's a forever stock that should keep winning this year and for the long term.

The TJX Companies (TJX +0.47%) has earned its reputation for providing value to both its customers and its long-term shareholders. Yet with shares up 34% over the past year and the stock now trading at roughly 32 times this year's earnings estimates, the value proposition for investors may be fading.

Operationally, the business remains strong. In the first quarter, same-store (comp) sales rose 6%, driven by higher customer traffic and spending per visit. The balanced growth across TJ Maxx, Marshalls, and HomeGoods, which posted an impressive 9% comp, shows the company continues to attract a broad range of customers.

The company's "treasure hunt" shopping experience has proven a durable advantage that resonates with younger shoppers. These Gen Z and millennial shoppers now account for a disproportionate number of its new customers, according to management.

TJX's margins are also expanding at a time when many retailers are facing pressure, with gross margin expanding by nearly 2 percentage points, reaching 31.3% in the quarter.

Image source: Getty Images

An opportunistic buying model The retailer's track record stems from its ability to capitalize on shifting fashion trends. While most companies struggle with excess inventory, the off-price retailer takes advantage, acquiring merchandise at deep discounts during times of distress.

The company leverages its relationships with over 21,000 vendors, giving it unmatched access to deals on brand-name goods. This allows TJX to sell brand-name and designer merchandise at prices typically 20% to 60% below those of traditional retailers. This value proposition continues to drive consistent traffic to its stores.

With over 5,200 stores globally, extending the growth story requires creativity. Management has outlined a pathway to an additional 1,800 stores within its current markets.

A significant portion of this growth is focused on the U.S. home furnishings market, which management estimates is worth over $30 billion. The company recently raised its long-term store target for HomeGoods in the U.S. from 1,000 to 1,800 locations.

This banner, along with its growing Homesense format, offers a source of profitable growth to complement its maturing apparel business while facing limited off-price competition.

Today's Change

(

0.47

%) $

0.78

Current Price

$

164.95

A high price for quality While the domestic growth story is compelling, international stores continue to report below-average profitability. TJX International's segment profit margin was just 4.6% in the first quarter, compared with the low-to-mid-teens for the rest of the business.

The company generated nearly $5 billion in free cash flow last year and maintains a strong balance sheet with $2.7 billion in net cash. This financial flexibility allows management to be patient, enabling it to invest in its next leg of growth, which could include entering a new category to expand its total addressable market.

After its strong run, the company needs to deliver on continued growth and margin expansion to drive returns from here. TJX remains one of the best-run companies in retail, and the off-price category remains a compelling space to invest, but at over 30 times earnings, patience may be the best approach.

The Federal Reserve decided to hold short-term interest rates steady at its recent meeting. While noting solid economic activity, the central bank also mentioned uncertainty caused by the Iran war. Eight members expect to keep rates the same this year, but nine project higher federal funds rates.

Subsequently, the U.S. and Iran signed a memorandum of understanding, giving the countries two months to work out an agreement, and oil prices subsequently slid. However, the situation remains fluid.

Given this uncertainty. TJX Companies (TJX +0.47%), with strong business fundamentals and growing dividends, offers investors an appealing potential total return.

Image source: Getty Images.

Drawing customers TJX's retail brands actually attract more customers during times of economic stress. Its chains, which include TJ Maxx, Marshalls, and HomeGoods, are off-price retailers selling apparel and home fashions.

That means they opportunistically purchase merchandise. And TJX has more leverage and buying opportunities during challenging economic times.

The company does well during ordinary times, but its sales growth has accelerated recently. That's due to consumers struggling with higher prices and an uncertain job market.

TJX's fiscal first-quarter 2027 same-store sales (comps) jumped 6%, with increases across all of its divisions. This helped drive its diluted earnings per share 29% higher. The results were for the period that ended on May 2. Management expects a very healthy 3% to 4% comps gain for the year.

Today's Change

(

0.47

%) $

0.78

Current Price

$

164.95

The company's not a mature retailer, either. It continues to open new locations, adding 48 in the first quarter and ending the quarter with 5,262 stores.

Higher payments Shareholders will also appreciate the regularly increasing dividend payments. The board of directors raised June's quarterly dividend by nearly 13% to $0.48 per share.

TJX has increased dividends for 29 out of the last 30 years. The exception came during the early days of the COVID-19 pandemic in 2020, when the company took the understandable decision to suspend payouts.

Investors shouldn't worry about TJX's ability to afford the payments. The stock has a payout ratio, or dividends compared to earnings, of just 34%.

The shares have a 1.2% dividend yield, based on the new quarterly dividend rate. That might not sound exciting, but it's higher than the S&P 500 index's 1.1%. Besides, investors can count on receiving higher dividends down the road.

The dividend yield combined with TJX's capital appreciation potential makes the stock a compelling buying opportunity for investors with a long-term view.

The TJX Companies demonstrate robust sales and profit growth across segments as a result of the poor consumer sentiment in the United States. Strong cash flow generation underpins TJX's ability to sustain dividends and buyback shares, although I have to question whether buybacks are actually attractive at the current valuation. Valuation metrics indicate a significant premium compared to the consumer discretionary sector median, as well as to the firm's own 5Y historic metrics.